Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 0 (Piperazines). Found 3 abstracts

Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology. 2005 Mar;6(2):115-20.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Molecular Pharmacology. 2004 May;65(5):1070-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 0 (Piperazines)

0 (Piperazines) Piperazines dt [Drug Therapy] 152459-95-5 (imatinib) Pyrimidines 0 (Pyrimidines) me [Metabolism] tu [Therapeutic Use] 0 (Protein Kinase Inhibitors) 0 (Antineoplastic Agents) Local Neoplasm Recurrence Neoplasm Staging Antineoplastic Agents NIH Research Support-Extramural 150-13-0 (4-Aminobenzoic Acid) EC 2-7-1-37 (Mitogen-Activated Protein Kinases) Drug Resistance EC 2-7-1-37 (JNK Mitogen-Activated Protein Kinases) Ovarian Neoplasms pd [Pharmacology] Protein Kinase Inhibitors ch [Chemistry] Mice Female Genital Neoplasms de [Drug Effects] Risk Assessment pc [Prevention & Control] SCID Mice Platelet-Derived Growth Factor Receptors ai [Antagonists & Inhibitors] EC 2-7-1-37 (p38 Mitogen-Activated Protein Kinases) Protein-Tyrosine Kinase 0 (Nitric Oxide Donors) EC 2-5-1-18 (glutathione S-transferase pi) EC 2-7-1-112 (Proto-Oncogene Proteins c-kit) cs [Chemical Synthesis] US Gov't Research Support-PHS Mutation Drug Administration Schedule 72025-60-6 (Leukotriene C4) pk [Pharmacokinetics] Enzyme Activation pa [Pathology] Multidrug Resistance-Associated Proteins Azo Compounds Drug Dose-Response Relationship Maximum Tolerated Dose Mitogen-Activated Protein Kinases Treatment Outcome 4-Aminobenzoic Acid 0 (Azo Compounds) mo [Mortality] Nitric Oxide Donors Biological Availability 3T3 Cells Leukotriene C4 Survival Analysis Proto-Oncogene Proteins c-kit 10102-43-9 (Nitric Oxide) Prodrugs Uterine Neoplasms Isoenzymes 4-dinitro-5-(N-methyl-N-4-carboxyphenylamino)phenyl 0 (O(2)-(2 N-dimethylamino)diazen-1-ium-1 1-N-2-diolate) 0 (Isoenzymes) Comparative Study Cell Division ge [Genetics] 0 (Multidrug Resistance-Associated Proteins) Glutathione Transferase Platelet-Derived Growth Factor) EC 2-7-1-112 (Receptors Female 0 (Prodrugs) Gastrointestinal Stromal Tumors Prognosis p38 Mitogen-Activated Protein Kinases Cultured Tumor Cells EC 2-7-1-112 (Protein-Tyrosine Kinase) aa [Analogs & Derivatives] EC 2-5-1-18 (Glutathione Transferase) 2-diolate) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1 JNK Mitogen-Activated Protein Kinases Nitric Oxide 4-dinitrophenyl) 0 (O(2)-(2
Last updated on Wednesday, February 05, 2020